Trial ID
NBF-006
Sponsor ID
Nitto BioPharma
A Phase 1/1b Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non-Small Cell Lung Cancer.
Principal Investigator
Alexander I. Spira, MD, PhD, FACPLocations
Fairfax Office
Learn More About This Trial
Other Relevant Trials
Trial ID
TAK-981-1502
Sponsor ID
Takeda Oncology
Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
1 Location
Trial ID
M20-111
Sponsor ID
AbbVie
“A Phase 1 first in human study evaluating safety and efficacy of ABBV-637 as either monotherapy or in combination in adult subjects with relapsed and refractory solid tumors”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP
1 Location
